Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.
Yi YangSiqi WangJiaoyang CaiJianwei LiangYingwen ZhangYangyang XieFei LuoJingyan TangYijin GaoShuhong ShenHaizhong FengYanxin LiPublished in: Cellular oncology (Dordrecht) (2022)
Our findings provide new insight into the mechanism by which ARHGEF12 regulates neuroblastoma tumorigenicity and suggest a translatable therapeutic approach by targeting ARHGEF12 with a small molecular inhibitor.